News Quantified

CTXR – citius pharmaceuticals, inc. (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

Citius Pharmaceuticals (CTXR) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $6.00 price target on the stock.

Citius Pharma (CTXR) Becomes Revenue-Generating With the Commercial Launch of LYMPHIR [Yahoo! Finance]

Citius Pharmaceuticals, Inc. Secures $3.8 million through New Jersey Economic Development Program

Citius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™ [Yahoo! Finance]

Citius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™

-7.1%

BEAT

Form 8-K Citius Pharmaceuticals, For: Mar 10

Form 8-K Citius Pharmaceuticals, For: Mar 04

Form ARS Citius Pharmaceuticals, For: Sep 30

Form DEFA14A Citius Pharmaceuticals,

Form DEF 14A Citius Pharmaceuticals, For: Apr 06

Top News Gainers

10/10 Form 4 Citius Pharmaceuticals, For: Oct 08 Filed by: Dutia Suren G 26.8%

4/1 Citius Signs Exclusive Option with Novellus to License Novel Stem-Cell Therapy for Acute Respiratory Distress Syndrome (ARDS) Associated with COVID-19 22.4%

4/28 Form 8-K Citius Pharmaceuticals, For: Apr 27 19.2%

10/15 Citius Pharmaceuticals to Present at the MicroCap Rodeo 14.1%

1/22 Form 8-K Citius Pharmaceuticals, For: Jan 22 13.0%

12/20 Form DEFA14A Citius Pharmaceuticals, 9.4%

2/13 Form 10-Q Citius Pharmaceuticals, For: Dec 31 8.9%

9/20 Citius Pharma -9.5% after filing to offer units [Seeking Alpha] 8.4%

5/15 Form 10-Q Citius Pharmaceuticals, For: Mar 31 7.6%

4/24 Form 424B3 Citius Pharmaceuticals, 7.5%

Top News Decliners

2/14 Form 8-K Citius Pharmaceuticals, For: Feb 14 -16.9%

9/23 Citius Pharmaceuticals Inc (NASDAQ: CTXR) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. -14.4%

4/29 Form 8-K Citius Pharmaceuticals, For: Apr 29 -12.4%

1/25 Citius Pharmaceuticals Inc (NASDAQ: CTXR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $4.00 price target on the stock. -10.3%

9/4 Form 8-K Citius Pharmaceuticals, For: Sep 04 -9.6%

3/4 Citius Pharmaceuticals Inc (NASDAQ: CTXR) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -8.3%

9/9 Citius Pharmaceuticals Inc (NASDAQ: CTXR) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. -8.2%

4/3 Citius Pharmaceuticals Inc (NASDAQ: CTXR) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -8.0%

2/3 Form 8-K Citius Pharmaceuticals, For: Jan 31 -7.6%

2/4 Citius Achieves 50% Patient Enrollment in Phase 3 Mino-Lok® Pivotal Trial -6.7%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day